About this Journal Submit a Manuscript Table of Contents
Lymphoma
Volume 2012 (2012), Article ID 290685, 10 pages
http://dx.doi.org/10.1155/2012/290685
Review Article

Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors

1Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia
2Department of Pathology, The University of Melbourne, Parkville, VIC 3010, Australia

Received 30 May 2012; Accepted 23 June 2012

Academic Editor: Vincent Ribrag

Copyright © 2012 Annabelle L. Rodd et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Willemze, E. S. Jaffe, G. Burg et al., “WHO-EORTC classification for cutaneous lymphomas,” Blood, vol. 105, no. 10, pp. 3768–3785, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Ponte, V. Serrão, and M. Apetato, “Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 6, pp. 716–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Krejsgaard, K. Kopp, E. Ralfkiaer et al., “A novel xenograft model of cutaneous T-cell lymphoma,” Experimental Dermatology, vol. 19, no. 12, pp. 1096–1102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. L. Edelson, “Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants,” Journal of the American Academy of Dermatology, vol. 2, no. 2, pp. 89–106, 1980. View at Scopus
  5. D. V. Kazakov, G. Burg, and W. Kempf, “Clinicopathological spectrum of mycosis fungoides,” Journal of the European Academy of Dermatology and Venereology, vol. 18, no. 4, pp. 397–415, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Girardi, P. W. Heald, and L. D. Wilson, “The pathogenesis of mycosis fungoides,” New England Journal of Medicine, vol. 350, no. 19, pp. 1978–1988, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. L. Edelson, “Outsmarting cutaneous T-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects,” Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 2, pp. S59–S62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Glass, K. L. Keller, J. L. Messina, et al., “The diagnosis and treatment of cutaneous T-cell lymphoma are challenging due the many clnical and histopathologic presentations of the disease,” Cancer Control, vol. 5, no. 1, 1998.
  9. R. Willemze, “Cutaneous T-cell lymphoma: epidemiology, etiology, and classification,” Leukemia and Lymphoma, vol. 44, supplement 3, pp. S49–S54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. P. T. Bradford, S. S. Devesa, W. F. Anderson, and J. R. Toro, “Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases,” Blood, vol. 113, no. 21, pp. 5064–5073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Girardi and R. L. Edelson, “Cutaneous T-cell lymphoma: pathogenesis and treatment,” Oncology, vol. 14, no. 7, pp. 1061–1070, 2000. View at Scopus
  12. E. Diamandidou, P. R. Cohen, and R. Kurzrock, “Mycosis fungoides and Sezary syndrome,” Blood, vol. 88, no. 7, pp. 2385–2409, 1996. View at Scopus
  13. A. Markova and M. A. Weinstock, “Trends in cutaneous lymphoma epidemiology,” Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 2, pp. S63–S66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B. D. Smith and L. D. Wilson, “Management of mycosis fungoides: Part 1. Diagnosis, staging, and prognosis,” Oncology, vol. 17, no. 9, pp. 1281–1288, 2003. View at Scopus
  15. R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel, “Primary cutaneous T-cell lymphoma: review and current concepts,” Journal of Clinical Oncology, vol. 18, no. 15, pp. 2908–2925, 2000.
  16. M. Girardi, P. W. Heald, and L. D. Wilson, “The pathogenesis of mycosis fungoides,” New England Journal of Medicine, vol. 350, no. 19, pp. 1978–1988, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Bunn and S. I. Lamberg, “Report of the committee on staging and classification of cutaneous T-cell lymphomas,” Cancer Treatment Reports, vol. 63, no. 4, pp. 725–728, 1979. View at Scopus
  18. F. Trautinger, R. Knobler, R. Willemze et al., “EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome,” European Journal of Cancer, vol. 42, no. 8, pp. 1014–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Dummer and M. Dreyling, “Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 19, supplement 2, pp. ii72–ii76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. M. Horwitz, E. A. Olsen, M. Duvic, P. Porcu, and Y. H. Kim, “Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach,” Journal of the National Comprehensive Cancer Network, vol. 6, no. 4, pp. 436–442, 2008. View at Scopus
  21. M. Girardi and R. L. Edelson, “Cutaneous T-cell lymphoma: pathogenesis and treatment,” Oncology, vol. 14, no. 7, pp. 1061–1070, 2000. View at Scopus
  22. J. Alibert, Description des Maladies de la Peau: Observees a L'HospitaL St. Louis, Barrois L'Aine et Fils, Paris, France, 1806.
  23. K. Ferenczi, R. C. Fuhlbrigge, J. L. Pinkus, G. S. Pinkus, and T. S. Kupper, “Increased CCR4 expression in cutaneous T cell lymphoma,” Journal of Investigative Dermatology, vol. 119, no. 6, pp. 1405–1410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Campbell, G. Haraldsen, J. Pan et al., “The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells,” Nature, vol. 400, no. 6746, pp. 776–780, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Vestergaard, K. Bang, B. Gesser, H. Yoneyama, K. Matsushima, and C. G. Larsen, “A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin,” Journal of Investigative Dermatology, vol. 115, no. 4, pp. 640–646, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Poligone, “Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma,” Core Evidence, vol. 6, pp. 1–12, 2011. View at Publisher · View at Google Scholar
  27. V. Kumar, N. Fausto, and A. Abbas, Robbins and Cotran Pathologic Basis of Disease, Elsevier Saunders, 9th edition, 2010.
  28. T. M. Kuzel, H. H. Roenigk, and S. T. Rosen, “Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy,” Journal of Clinical Oncology, vol. 9, no. 7, pp. 1298–1313, 1991. View at Scopus
  29. R. Van Doorn, C. W. Van Haselen, P. C. Van Voorst Vader et al., “Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients,” Archives of Dermatology, vol. 136, no. 4, pp. 504–510, 2000. View at Scopus
  30. S. J. Whittaker, J. R. Marsden, M. Spittle, and R. Russell Jones, “Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas,” British Journal of Dermatology, vol. 149, no. 6, pp. 1095–1107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. F. J. Kaye, P. A. J. Bunn, S. M. Stinberg, et al., “A randomized trial comparing combination electro beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides,” The New England Journal of Medicine, vol. 321, no. 26, pp. 1748–1790, 1989.
  32. H. S. Zackheim, M. Kashani-Sabet, and S. Amin, “Topical corticosteroids for mycosis fungoides: experience in 79 patients,” Archives of Dermatology, vol. 134, no. 8, pp. 949–954, 1998. View at Scopus
  33. H. S. Zackheim, M. Kashani-Sabet, and S. Amin, “Topical corticosteroids for mycosis fungoides: experience in 79 patients,” Archives of Dermatology, vol. 134, no. 8, pp. 949–954, 1998. View at Scopus
  34. D. Breneman, M. Duvic, T. Kuzel, R. Yocum, J. Truglia, and V. J. Stevens, “Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma,” Archives of Dermatology, vol. 138, no. 3, pp. 325–332, 2002. View at Scopus
  35. C. J. Karzmark, “Total skin electron therapy: technique and dosimetry,” American Association of Physicists in Medicine Report 23, 1987.
  36. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. P. A. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly, “Histone deacetylases and cancer: causes and therapies,” Nature Reviews Cancer, vol. 1, no. 3, pp. 194–202, 2001. View at Scopus
  38. M. Dokmanovic, C. Clarke, and P. A. Marks, “Histone deacetylase inhibitors: overview and perspectives,” Molecular Cancer Research, vol. 5, no. 10, pp. 981–989, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. A. Marks, “Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions,” Biochimica et Biophysica Acta, vol. 1799, no. 10–12, pp. 717–725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Minucci and P. G. Pelicci, “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer,” Nature Reviews Cancer, vol. 6, no. 1, pp. 38–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Tumber, L. S. Collins, K. D. Petersen et al., “The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 2, pp. 275–283, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Tan, S. Cang, Y. Ma, R. L. Petrillo, and D. Liu, “Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents,” Journal of Hematology and Oncology, vol. 3, article 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Akazawa and I. Komuro, “Roles of cardiac transcription factors in cardiac hypertrophy,” Circulation Research, vol. 92, no. 10, pp. 1079–1088, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Thiagalingam, K. H. Cheng, H. J. Lee, N. Mineva, A. Thiagalingam, and J. F. Ponte, “Histone deacetylases: unique players in shaping the epigenetic histone code,” Annals of the New York Academy of Sciences, vol. 983, pp. 84–100, 2003. View at Scopus
  46. C. L. Peterson and M. A. Laniel, “Histones and histone modifications,” Current Biology, vol. 14, no. 14, pp. R546–551, 2004. View at Scopus
  47. P. A. Marks, V. M. Richon, and R. A. Rifkind, “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells,” Journal of the National Cancer Institute, vol. 92, no. 15, pp. 1210–1216, 2000. View at Scopus
  48. S. Cang, Y. Ma, and D. Liu, “New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer,” Journal of Hematology and Oncology, vol. 2, article 22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Y. Roth, J. M. Denu, and C. D. Allis, “Histone acetyltransferases,” Annual Review of Biochemistry, vol. 70, pp. 81–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. B. C. Smith and J. M. Denu, “Chemical mechanisms of histone lysine and arginine modifications,” Biochimica et Biophysica Acta, vol. 1789, no. 1, pp. 45–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. H. Kuo, “Roles of histone acetyltransferases and deacetylases in gene regulation,” BioEssays, vol. 20, no. 8, pp. 615–626, 1998.
  52. J. C. Kim, E. S. Shin, C. W. Kim et al., “In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer,” Anticancer Research, vol. 29, no. 8, pp. 3027–3034, 2009. View at Scopus
  53. S. G. Gray and T. J. Ekström, “The human histone deacetylase family,” Experimental Cell Research, vol. 262, no. 2, pp. 75–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. P. A. Marks, V. M. Richon, and R. A. Rifkind, “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells,” Journal of the National Cancer Institute, vol. 92, no. 15, pp. 1210–1216, 2000. View at Scopus
  55. A. J. M. De Ruijter, A. H. Van Gennip, H. N. Caron, S. Kemp, and A. B. P. Van Kuilenburg, “Histone deacetylases (HDACs): characterization of the classical HDAC family,” Biochemical Journal, vol. 370, no. 3, pp. 737–749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. X. J. Yang and E. Seto, “Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression,” Current Opinion in Genetics and Development, vol. 13, no. 2, pp. 143–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. T. A. Miller, D. J. Witter, and S. Belvedere, “Histone deacetylase inhibitors,” Journal of Medicinal Chemistry, vol. 46, no. 24, pp. 5097–5116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Cang, Y. Ma, and D. Liu, “New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer,” Journal of Hematology and Oncology, vol. 2, article 22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Siegel, M. Hussein, C. Belani et al., “Vorinostat in solid and hematologic malignancies,” Journal of Hematology and Oncology, vol. 2, article 31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Ellis, P. W. Atadja, and R. W. Johnstone, “Epigenetics in cancer: targeting chromatin modifications,” Molecular Cancer Therapeutics, vol. 8, no. 6, pp. 1409–1420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. H. M. Prince, M. J. Bishton, and R. W. Johnstone, “Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors,” Future Oncology, vol. 5, no. 5, pp. 601–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur, “FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma,” Oncologist, vol. 12, no. 10, pp. 1247–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., “Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109–3115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Crump, B. Coiffier, E. D. Jacobsen et al., “Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma,” Annals of Oncology, vol. 19, no. 5, pp. 964–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. W. K. Kelly, O. A. O'Connor, L. M. Krug et al., “Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3923–3931, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Sabharwal and D. Kerr, “Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future,” Expert Review of Anticancer Therapy, vol. 7, no. 4, pp. 477–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. K. B. Hymes, “The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-Cell lymphoma,” Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 2, pp. 98–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Mercurio, S. Minucci, and P. G. Pelicci, “Histone deacetylases and epigenetic therapies of hematological malignancies,” Pharmacological Research, vol. 62, no. 1, pp. 18–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. R. L. Piekarz, R. Frye, M. Turner et al., “Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Dickinson, R. W. Johnstone, and H. M. Prince, “Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect,” Investigational New Drugs, vol. 28, no. 1, pp. S3–S20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Sandor, S. Bakke, R. W. Robey et al., “Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms,” Clinical Cancer Research, vol. 8, no. 3, pp. 718–728, 2002. View at Scopus
  72. A. Saito, T. Yamashita, Y. Mariko et al., “A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4592–4597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Jona, N. Khaskhely, D. Buglio, et al., “The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors,” Experimental Hematology, vol. 39, no. 10, pp. 1007.e1–1017.e1, 2011.
  74. K. R. Suchin, M. Cassin, S. L. Gottleib et al., “Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12,” Journal of the American Academy of Dermatology, vol. 44, no. 1, pp. 28–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. B. R. Vowels, M. Cassin, E. C. Vonderheid, and A. H. Rook, “Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells,” Journal of Investigative Dermatology, vol. 99, no. 1, pp. 90–94, 1992. View at Scopus
  76. B. R. Vowels, S. R. Lessin, M. Cassin et al., “Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma,” Journal of Investigative Dermatology, vol. 103, no. 5, pp. 669–673, 1994. View at Scopus
  77. K. Asadullah, W. D. Döcke, A. Haeuler, W. Sterry, and H. D. Volk, “Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA,” Journal of Investigative Dermatology, vol. 107, no. 6, pp. 833–837, 1996. View at Scopus
  78. P. Gimsing, “Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor,” Expert Opinion on Investigational Drugs, vol. 18, no. 4, pp. 501–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Qian, G. Ara, E. Mills, W. J. LaRochelle, H. S. Lichenstein, and M. Jeffers, “Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer,” International Journal of Cancer, vol. 122, no. 6, pp. 1400–1410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Gimsing, M. Hansen, L. M. Knudsen et al., “A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia,” European Journal of Haematology, vol. 81, no. 3, pp. 170–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. N. L. Steele, J. A. Plumb, L. Vidal et al., “A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors,” Clinical Cancer Research, vol. 14, no. 3, pp. 804–810, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. S. Ramalingam, C. P. Belani, C. Ruel et al., “Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma,” Journal of Thoracic Oncology, vol. 4, no. 1, pp. 97–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. W. Shao, J. D. Growney, Y. Feng, et al., “Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models,” Proceedings of the 99th American Association of Cancer Research Annual Meeting, April 2008.
  84. P. Atadja, “Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges,” Cancer Letters, vol. 280, no. 2, pp. 233–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Duvic, J. C. Becker, and S. Dalle, “Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL),” in Proceedings of the ASH Annual Meeting Abstracts, vol. 112, p. 1005, 2008.
  86. C. Zhang, V. Richon, X. Ni, R. Talpur, and M. Duvic, “Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action,” Journal of Investigative Dermatology, vol. 125, no. 5, pp. 1045–1052, 2005. View at Publisher · View at Google Scholar · View at Scopus